Current chemotherapy drugs are very effective for Hodgkin’s lymphomas but patients who relapse after receiving them don;t do as well. This is because the cancers develop resistance to the se drugs. Zolinza is a new drug approved in the USA for the treatment of cutaneous(skin) T-cell lymphoma who have progressive, persistent or recurrent disease or following two systemic therapies. It may be effective for Hodgkin’s. For Hodgkin’s, a phase II study enrolled twenty-five eligible patients. The overall resposne rate was low, 4% (one partial response), but the drug was well tolerated. A phase I clinical trial treated several types of lymphoma. The best responses were seen in those with Hodgkin and diffuse large B-cell lymphoma (Budde et al). A study of Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma was started at the City of Hope but was terminated.
For Professional version see here